Growth charts for individuals with mucopolysaccharidosis VI (Maroteaux–Lamy syndrome)

JIMD Reports

Volumn 18, Issue , 2015, Pages 1-11

  Quartel, Adrian ^a   Hendriksz, Christian J ^b   Parini, Rossella ^c   Graham, Sue ^a   Lin, Ping ^a   Harmatz, Paul ^d  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c SAN GERARDO HOSPITAL   (Italy)

^d CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

BioMarin pharmaceutical; Growth chart; Reference growth chart; Schwarz bayesian criterion; uGAG level

Indexed keywords

EID: 84951269854     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2014_333     Document Type: Chapter

References (42)

1. Abreu S, Hayden J, Berthold P et al (1995) Growth plate pathology in feline mucopolysaccharidosis VI. Calcif Tissue Int 57(3):185–190
2. Alliston T (2010) Chondroitin sulfate and growth factor signaling in the skeleton: possible links to MPS VI. J Pediatr Rehabil Med 3(2):129–138
3. Borges MF, Tavares FS, Silva PCL et al (2003) Mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome): endocrine evaluation of three cases. Arq Bras Endocrinol Metab 47(1):87–94
4. Buyukgebiz B, Eroglu Y, Kovanlikaya I, Sen A, Buyukgebiz A (1995) Maroteaux–Lamy syndrome associated with growth hormone deficiency. J Pediatr Endocrinol Metab 8(4):305–307
5. Cole TJ (1989) Using the LMS method to measure skewness in the NCHS and Dutch National height standards. Ann Hum Biol 16 (5):407–419
6. Cole TJ, Green PJ (1992) Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med 11(10):1305–1319
7. de Ruijter J, Broere L, Mulder MF et al (2013) Growth in patients with mucopolysaccharidosis type III (Sanfilippo disease). J Inherit Metab Dis. doi:10.1007/s10545-10013-96583
8. Decker C, Yu Z-F, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 3(2):89–100
9. Furujo M, Kubo T, Kosuga M, Okuyama T (2011) Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol Genet Metab 104(4):597–602
10. Gallegos-Arreola MP, Machorro-Lazo MV, Flores-Martinez SE et al (2000) Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses. Arch Med Res 31(5):505–510
11. Gardner CJ, Robinson N, Meadows T et al (2011) Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H). J Inherit Metab Dis 34(2):489–497
12. Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120(2):405–418
13. Giugliani R, Lampe C, Guffon N et al (2014) Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy Syndrome)—10 year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet Part A. doi:10.1002/ajmg.a.36584
14. Gray G, Claridge P, Jenkinson L, Green A (2007) Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses: an evaluation. Ann Clin Biochem 44(Pt 4):360–363
15. Hall JG, Allanson JE, Gripp KW, Slavotinek AM (2012) Special section. Syndrome-specific growth charts. Am J Med Genet A 158A(11):2645–2646
16. Harmatz P, Whitley C, Waber L et al (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux–Lamy syndrome). J Pediatr 144(5):574–580
17. Harmatz P, Ketteridge D, Giugliani R et al (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115(6)
18. Harmatz P, Giugliani R, Schwartz I et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148(4):533–539
19. Harmatz P, Giugliani R, Schwartz IV et al (2008) Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94(4):469–475
20. Harmatz PR, Garcia P, Guffon N et al (2013) Galsulfase (Naglazyme (R)) therapy in infants with mucopolysaccharidosis VI. J Inherit Metab Dis. doi:10.1007/s10545-013-9654-7
21. Hendriksz C, Giugliani R, Harmatz P et al (2013) Design, baseline characteristics, and early findings of the MPS VI (mucopolysac-charidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis 36(2):373–384
22. Heron D, Baumann C, Benichou JJ, Harpey JP, Le Merrer M (2004) Early diagnosis of Maroteaux–Lamy syndrome in two patients with accelerated growth and advanced bone maturation. Eur J Pediatr 163(6):323–326
23. Horovitz DD, Magalhaes TS, Acosta A et al (2013) Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab 109(1):62–69
24. Horton WA, Hall JG, Scott CI, Pyeritz RE, Rimoin DL (1982) Growth curves for height for diastrophic dysplasia, spondyloepiphyseal dysplasia congenita, and pseudoachondroplasia. Am J Dis Child 136(4):316–319
25. Jurecka A, Zakharova E, Cimbalistiene L et al (2013) Mucopolysaccharidosis type VI in Russia, Kazakhstan, and Central and Eastern Europe. Pediatr Int. doi:10.1111/ped.12281
26. Kantaputra PN, Kayserili H, Guven Y et al (2014) Clinical manifestations of 17 patients affected with mucopolysaccharidosis type VI and eight novel ARSB mutations. Am J Med Genet Part A 164(6):1443–1453
27. Karageorgos L, Brooks DA, Pollard A et al (2007) Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 28(9):897–903
28. Kuczmarski R, Ogden C, Guo S et al (2002) 2000 CDC growth charts for the United States: Methods and development. Vital Health Stat 11(246):1–190
29. Lachman R, Martin KW, Castro S, Basto MA, Adams A, Teles EL (2010) Radiologic and neuroradiologic findings in the mucopolysaccharidoses. J Pediatr Rehabil Med 3(2):109–118
30. Neufeld EF, Muenzer J (2013) The mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G (eds) OMMBID – the online metabolic and molecular bases of inherited diseases. McGraw-Hill, New York. http://ommbid.mhmedical.com/content.aspx? bookid=474&Sectionid=45374136. Accessed 23 Jan 2014
31. Polgreen LE, Tolar J, Plog M et al (2008) Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant 41(12):1005–1011
32. Polgreen LE, Thomas W, Fung E et al (2014) Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI. J Clin Densitom 17(1):200–206
33. Ranke MB (1989) Disease-specific growth charts–do we need them? Acta Paediatr Scand Suppl 356:17–25
34. Scarpa M, Barone R, Fiumara A et al (2009) Mucopolysaccharidosis VI: the Italian experience. Eur J Pediatr 168(10):1203–1206
35. Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH (2010) Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 107(1):222–227
36. Swiedler S, Beck M, Bajbouj M et al (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux–Lamy syndrome). Am J Med Genet A 134A(2):144–150
37. Tarquinio DC, Motil KJ, Hou W et al (2010) Growth failure and outcome in Rett syndrome: specific growth references. Neurology 79(16):1653–1661
38. Tomatsu S, Montaño A, Oikawa H et al (2012) Impairment of body growth in mucopolysaccharidoses. In: Preedy V (ed) Handbook of growth and growth monitoring in health and disease. Springer, New York, pp 2091–2117
39. Tylki-Szymanska A, Rozdzynska A, Jurecka A, Marucha J, Czartoryska B (2010) Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase). Mol Genet Metab 99(1):10–17
40. von Muhlendahl KE, Bradac GB (1975) Empty Sella syndrome in a boy with mucopolysaccharidosis type VI (Maroteaux–Lamy). Helv Paediatr Acta 30(2):185–190
41. White K (2011) Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 50(Suppl 5):26–33
42. Whitley CB, Ridnour MD, Draper KA, Dutton CM, Neglia JP (1989) Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 35(3):374–379